Prof. Dr. Meral Beksaç

Extracorporeal photochemotherapy in mycosis fungoides,Photochimiothérapie extracorporelle dans les mycoses fongiques

Transfusion Clinique et Biologique, 2017

DOI 10.1016/j.tracli.2017.05.001 PMID 28578935 10 atıf (Europe PMC) Kaynak: ORCID

Flow cytometric aldehyde dehydrogenase assay enables a fast and accurate human umbilical cord blood hematopoietic stem cell assessment,İnsan göbek kordon kanı hematopoetik kök hücre değerlendirmesinde hızlı ve etkin bir değerlendirme yöntemi: Akım sitometrik aldehit dehidrogenaz testi

Turkish Journal of Hematology, 2017

DOI 10.4274/tjh.2016.0214 PMID 27956370 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Management and Outcome of Central Nervous System (CNS) Involvement in Acute Lymphoblastic Leukemia (ALL)

Biology of Blood and Marrow Transplantation, 2017

DOI 10.1016/j.bbmt.2016.12.419 Açık erişimli tam metinKaynak: ORCID

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study

Leukemia, 2017

DOI 10.1038/leu.2017.138 PMID 28620163 279 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial

British Journal of Haematology, 2017

DOI 10.1111/bjh.14821 PMID 28653400 19 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma

British Journal of Haematology, 2017

DOI 10.1111/bjh.14483 PMID 28005265 39 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the European myeloma network

Leukemia, 2017

DOI 10.1038/leu.2017.353 PMID 29251284 4 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Subsequent malignancies after allogeneic hematopoietic stem cell transplantation

Clinical Transplantation, 2017

DOI 10.1111/ctr.12987 PMID 28432802 6 atıf (Europe PMC) Kaynak: ORCID

Autologous Stem Cell Transplantation Versus Bortezomib-Melphalan-Prednisone for Newly Diagnosed Multiple Myeloma: Second Interim Analysis of the Phase 3 EMN02/HO95 Study

Pure Amsterdam UMC, 2017

46 atıf (OpenAlex) Kaynak: OpenAlex

Heparin enhances CD34+ content of stem cells collected following G-CSF +/- chemotherapy

Cytotherapy, 2017

DOI 10.1016/j.jcyt.2017.03.031 2 atıf (OpenAlex) Kaynak: OpenAlex

Ex vivo expansion of human umbilical cord blood Hematopoietic Stem Cells (HSCs) with Valproic Acid (VPA) or Neurotrophic Factor (NTF)

Cytotherapy, 2017

DOI 10.1016/j.jcyt.2017.02.139 1 atıf (OpenAlex) Kaynak: OpenAlex

Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantations for acute myeloid leukemia.

Journal of Clinical Oncology, 2017

DOI 10.1200/jco.2017.35.15_suppl.e18518 Kaynak: OpenAlex

A single center experience with two decades of follow-up on patients with hairy cell leukemia.

Journal of Clinical Oncology, 2017

DOI 10.1200/jco.2017.35.15_suppl.e18530 Kaynak: OpenAlex

Dilemma-High Response Rates Vs High Toxicity: Autologous Stem Cell Transplantation for Lymphoma

Blood, 2017

DOI 10.1182/blood.v130.suppl_1.5528.5528 Kaynak: OpenAlex

Multicenter Early Access Program Results from Turkey: Efficacy and Safety of Daratumumab Among Heavily Pretreated Relapse/Refractory Multiple Myeloma Patients

Blood, 2017

DOI 10.1182/blood.v130.suppl_1.5442.5442 Kaynak: OpenAlex

A Preliminary Analysis of Inherited Immune Checkpoint Control in Multiple Myeloma: Relative Frequency of Inhibitory or Activating Type Killer Immunoglobulin like Receptors and Their Cognate Ligands HLA-C1 and -C2

Blood, 2017

DOI 10.1182/blood.v130.suppl_1.4977.4977 Kaynak: OpenAlex

Age Is Not Important for Autologous Peripheral Hematopoietic Stem Cell Transplantation in Multiple Myeloma

Blood, 2017

DOI 10.1182/blood.v130.suppl_1.5480.5480 Kaynak: OpenAlex

İnsan Göbek Kordon Kanı Hematopoetik Kök Hücre Değerlendirmesinde Hızlı ve Etkin Bir Değerlendirme Yöntemi: Akım Sitometrik Aldehit Dehidrogenaz Testi

Turkish Journal of Hematology, 2017

Açık erişimli tam metinKaynak: OpenAlex

Total Blood Lymphocyte Count Alteration During and after Pregnancy

Gynecology Obstetrics and Reproductive Medicine, 2016

DOI 10.21613/gorm.2016.633 10 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

Ex Vivo Expansion of Human Umblical Cord Blood Hematopoietic Stem Cells (HSC) with Valproic Acid or Notch-Ligand +/− Fibronectin

Cytotherapy, 2016

DOI 10.1016/j.jcyt.2016.03.094 Kaynak: OpenAlex

A case of superwarfarin poisoning due to repetitive occupational dermal rodenticide exposure in a worker,Tekrarlayan mesleksel deri maruziyetine bağli süpervarfarin zehirlenmesi gelişen bir işçi olgusu

Turkish Journal of Hematology, 2016

DOI 10.4274/tjh.2015.0433 PMID 27093901 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice

American Journal of Hematology, 2016

DOI 10.1002/ajh.24351 PMID 26955792 105 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Daratumumab, bortezomib, and dexamethasone for multiple myeloma

New England Journal of Medicine, 2016

DOI 10.1056/nejmoa1606038 PMID 27557302 1.175 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Editorial: "How to improve cord blood transplantation: By enhancing cell counts or engraftment?"

Frontiers in Medicine, 2016

DOI 10.3389/fmed.2016.00020 PMID 27243013 Açık erişimli tam metinKaynak: ORCID

HLA polymorphism and risk of multiple myeloma

Leukemia, 2016

DOI 10.1038/leu.2016.199 PMID 27461064 22 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

How to improve cord blood engraftment?

Frontiers in Medicine, 2016

DOI 10.3389/fmed.2016.00007 PMID 26925402 10 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Is there any reason to prefer cord blood instead of adult donors for hematopoietic stem cell transplants?

Frontiers in Medicine, 2016

DOI 10.3389/fmed.2015.00095 PMID 26793711 4 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

The Lancet Haematology, 2016

DOI 10.1016/s2352-3026(16)30147-8 PMID 27751707 122 atıf (Europe PMC) Kaynak: ORCID

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by prior treatment

Blood, 2016

DOI 10.1182/blood-2015-09-665018 PMID 26631116 114 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)

Blood, 2016

DOI 10.1182/blood.v128.22.673.673 43 atıf (OpenAlex) Kaynak: OpenAlex

Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial)

Blood, 2016

DOI 10.1182/blood.v128.22.242.242 35 atıf (OpenAlex) Kaynak: OpenAlex

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Blood, 2016

DOI 10.1182/blood.v128.22.4414.4414 31 atıf (OpenAlex) Kaynak: OpenAlex

Lomeguatrib, a O6-Methylguanine-DNA-Methyltransferase (MGMT) Inhibitor, Induces DNA Damage Induced Apoptosis By Targeting Double-Strand DNA Repair in Multiple Myeloma

Blood, 2016

DOI 10.1182/blood.v128.22.2103.2103 2 atıf (OpenAlex) Kaynak: OpenAlex

Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR

Annals of Oncology, 2016

DOI 10.1093/annonc/mdw375.01 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.

Journal of Clinical Oncology, 2016

DOI 10.1200/jco.2016.34.18_suppl.lba4 22 atıf (OpenAlex) Kaynak: OpenAlex

Two phase 3 studies of the oral proteasome inhibitor (PI) ixazomib for multiple myeloma (MM) in the maintenance setting: TOURMALINE-MM3, and -MM4.

Journal of Clinical Oncology, 2016

DOI 10.1200/jco.2016.34.15_suppl.tps8068 7 atıf (OpenAlex) Kaynak: OpenAlex

Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.

Journal of Clinical Oncology, 2016

DOI 10.1200/jco.2016.34.15_suppl.lba4 5 atıf (OpenAlex) Kaynak: OpenAlex

Age as a decision factor for doing autologous stem cell transplantation in fit patients with myeloma and lymphoma.

Journal of Clinical Oncology, 2016

DOI 10.1200/jco.2016.34.15_suppl.e19001 Kaynak: OpenAlex

Therapeutic Plasma Exchange for Thrombotic Microangiopathy

Blood, 2016

DOI 10.1182/blood.v128.22.4939.4939 Kaynak: OpenAlex

Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, nordic and turkish myeloma study groups

Acta Haematologica, 2015

DOI 10.1159/000370023 PMID 25824293 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Effects of in utero cord blood collection on post-cesarean hemoglobin levels

European Journal of Obstetrics and Gynecology and Reproductive Biology, 2015

DOI 10.1016/j.ejogrb.2015.07.022 PMID 26295789 Açık erişimli tam metinKaynak: ORCID

Elotuzumab therapy for relapsed or refractory multiple myeloma

New England Journal of Medicine, 2015

DOI 10.1056/nejmoa1505654 PMID 26035255 1.049 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

European myeloma network guidelines for the management of multiple myeloma-related complications

Haematologica, 2015

DOI 10.3324/haematol.2014.117176 PMID 26432383 259 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Impact of "killer immunoglobulin-like receptor/ligand" genotypes on outcome following surgery among patients with colorectal cancer: Activating KIRs are associated with long-term disease free survival

PLoS ONE, 2015

DOI 10.1371/journal.pone.0132526 PMID 26181663 20 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: Results from the EBMT NMAM2000 prospective trial

Bone Marrow Transplantation, 2015

DOI 10.1038/bmt.2014.310 PMID 25621805 15 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Insight into human protease activated receptor-1 as anticancer target by molecular modelling

SAR and QSAR in Environmental Research, 2015

DOI 10.1080/1062936x.2015.1095799 PMID 26501801 5 atıf (Europe PMC) Kaynak: ORCID

Panobinostat: A novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma

Expert Review of Anticancer Therapy, 2015

DOI 10.1586/14737140.2015.1047770 PMID 26051506 52 atıf (Europe PMC) Kaynak: ORCID

Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation

European Journal of Haematology, 2015

DOI 10.1111/ejh.12491 PMID 25402977 29 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study

Blood, 2015

DOI 10.1182/blood.v126.23.4201.4201 4 atıf (OpenAlex) Kaynak: OpenAlex

Hepatitis B (HBV) Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Lenalidomide Containing Regimens: A Single Center Experience

Blood, 2015

DOI 10.1182/blood.v126.23.5377.5377 3 atıf (OpenAlex) Kaynak: OpenAlex